Dr. Sharon joined The National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program in 2011 as a senior investigator in the Investigational Drug Branch, where he works with academic investigators and industry collaborators to carry out the clinical development of promising new cancer therapies. His current portfolio includes immunotoxins, antibody-drug conjugates, immune-based monoclonal antibodies and other targeted agents.
Dr. Sharon received his M.D. from Baylor College of Medicine and completed his internal medicine residency at Emory University, where he continued to work as a hospitalist and clinical instructor. He completed his hematology/oncology fellowship at the National Institutes of Health, and concurrently obtained a master of public health degree at the Harvard School of Public Health. His research at the NCI focused on mesothelioma and clinical investigations of targeted therapies, including immunotoxins. Other projects included clinical and translational projects aimed at decreasing immunogenic responses in the host immune system. Dr. Sharon also has a particular interest in clinical effectiveness and comparative health systems.
He previously worked as a guest at the Brookings Institution, helping to plan and manage panels for the Brookings Institution’s inaugural Conference on Clinical Cancer Research, whose aim was to find consensus among stakeholders to find solutions to critical questions regarding the future of clinical cancer research. He has served as a reviewer for journals such as Mabs, Value in Health, and Clinical Cancer Research.